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Cystic fibrosis (CF) is an inherited disorder where individual disease etiology and response
to therapeutic intervention is impacted by CF transmembrane regulator (CFTR) mutations
and other genetic modifiers. CFTR regulates multiple mechanisms in a diverse range of
epithelial tissues. In this Review, we consolidate the latest updates in the development
of primary epithelial cellular model systems relevant for CF. We discuss conventional
two-dimensional (2-D) airway epithelial cell cultures, the backbone of in vitro cellular
models to date, as well as improved expansion protocols to overcome finite supply of the
cellular source. We highlight a range of strategies for establishment of three dimensional
(3-D) airway and intestinal organoid models and evaluate the limitations and potential
improvements in each system, focusing on their application in CF. The in vitro CFTR
functional assays in patient-derived organoids allow for preclinical pharmacotherapy
screening to identify responsive patients. It is likely that organoids will be an invaluable
preclinical tool to unravel disease mechanisms, design novel treatments, and enable
clinicians to provide personalized management for patients with CF.
Keywords: cystic fibrosis, organoid, personalized medicine, CFTR, drug development, sweat chloride, CFTR
modulator
INTRODUCTION
Cystic Fibrosis (CF; OMIM 219700) is the most common life-limiting, autosomal recessive
monogenic disease in Caucasian populations (Riordan, 2008). It is caused by mutations in the
gene encoding CF transmembrane conductance regulator (CFTR), an anion channel essential for
regulating trans-epithelial secretion of chloride (Cl−) and bicarbonate (HCO−3 ). The loss of CFTR
function leads to abnormalities at the mucosal surfaces in multiple exocrine organs including the
lungs, pancreas, liver, and intestine. Notably however, progressive lung disease and respiratory
failure are the major cause of morbidity and mortality for most patients (Ratjen et al., 2015). While
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the regulatory role of CFTR in ion and fluid transport is widely
known, the exact mechanism of its defect in the development
of CF remains debatable. Two competing hypotheses attempt to
explain CF pathogenesis; (1) the “high salt” hypothesis postulates
that diminished trans-epithelial Cl− conductance associated with
CFTR dysfunction results in increased retention of salt at the
mucosal surface, which negates the activity of antimicrobial
peptides present in the epithelial apical secretions (Zabner
et al., 1998; Wine, 1999); (2) the more favorable “low volume”
hypothesis suggests the lack of epithelial sodium channel (ENaC)
inhibition in the absence of CFTR function causes sodium (Na+)
hyper-absorption, with accompanying intracellular flux of Cl−
and water (Matsui et al., 1998; Wine, 1999). Mucus becomes
dehydrated, viscous and sticky which then leads to decreased
airway surface liquid (ASL) height, as well as mucus stasis and
obstruction (Riordan, 2008). Irrespective of the mechanism of
action, impaired mucociliary clearance in the lung and the innate
inability to eradicate inhaled pathological agents are hallmarks of
CF. Recurrent cycles of lung infection and exacerbations result
in chronic inflammatory responses which then lead to structural
lung damage, loss of lung function, and ultimately respiratory
insufficiency (Ratjen et al., 2015).
Major advances in symptom management have been
instrumental in delaying disease progression in CF.
Administration of enzyme replacement therapy, nutritional
support, mucolytic agents airway clearance techniques, and
antibiotics for bacterial lung infection, along with early detection
of disease (newborn screening, pathogen surveillance) has
dramatically improved life expectancy in CF patients over the
last 4 decades. The median age of death is now above 40 years
(Keogh et al., 2018). Importantly, a class of small molecule
compounds termed CFTR modulators were recently discovered.
These compounds directly correct defective CFTR protein in CF
patients and have now transformed the therapeutic landscape
of CF in a precision-based fashion. The first part of this
review outlines the current developments in CFTR modulators
addressing the different dysfunctional CFTR mutation class and
highlights the need for individualized strategies to restore their
function.
The second part of this review discusses the evolving use of
different epithelial cell models and reporter assays for assessing
clinical response to CFTR-directed drugs on a personalized basis,
and highlights the strengths and limitations of each application.
This review also elaborates on the breakthrough discoveries
of long-term cultures of patient-derived 3-dimentional (3-D)
Abbreviations: 2-D, 2-Dimensional; 3-D, 3-Dimensional; ALI, Air-liquid
interface; ASL, Airway surface liquid; BAL, Bronchoalveolar lavage; BEGM,
Bronchial epithelial growth media; BMI, Body mass index; BMP, Bone
morphogenic protein; CaCC, Calcium-activated chloride channels; CF, Cystic
Fibrosis; CFTR, Cystic Fibrosis transmembrane conductance regulator; Cl−,
Chloride; CRCs, Conditionally reprogrammed cells; DMSO, Dimethyl sulfoxide;
ECM, Extracellular matrix; ENaC, Epithelial sodium channel; FEV1, Forced
expiratory volume—one second; FIS, Forskolin-induced swelling; FRT, Fischer
rat thyroid; HAE, Human airway epithelial; HBE, Human bronchial epithelial;
HCO−3 , Bicarbonate; HNE, Human nasal epithelial; HTS, High-throughput
screening; ICM, Intestinal current measurement; Na+, Sodium; P#, Passage #;
PTC, Premature termination codon; ROCK, Rho-associated protein kinase; TEER,
Trans-epithelial electrical resistance; TGF-β, Transforming growth factor-beta.
airway and rectal organoids. We also discuss their emerging use
as ex vivo biomarkers and preclinical predictive tools for the
disease.
CURRENT CFTR-BASED THERAPY WITH
CFTR MODULATORS
More than 2,000 CFTR mutations have been identified so far
and at least 336 of these are reported to lead to symptoms
characteristic of CF (Cystic Fibrosis Mutations Database report
31 August 2018 (US CF Foundation, 2011). It is thus perceivable
that a multi-pronged approach is required to target the different
defective mechanisms that each CFTR mutation confers. For the
past 15 years, high-throughput screening (HTS) has accelerated
the process of drug discovery. To identify candidate CFTR
modulators, hundreds of thousands of chemical compounds
with diverse structures were screened and the potential of a
compound to rescue or activate CFTRwas tested in cellular-based
assays (Pedemonte et al., 2005; Van Goor et al., 2006; Sutanto
et al., 2018). The promising compounds, called “hits,” underwent
further medicinal and chemical optimization to improve potency
and minimize potential off-target activities of the compounds.
This process has led to successful identification of multiple
compounds, some of which have moved forward to human
clinical trials.
The different approaches targeted toward correcting each
CFTR mutation class as well as the compounds currently tested
in clinical trials are summarized in Table 1. CFTR-modulating
compounds are classified into five main groups: read-through
agents, correctors, potentiators, stabilizers, and amplifiers. Of
these, two classes of modulators (potentiators and correctors)
have gained regulatory approval to treat CF patients with specific
CFTR mutations.
Potentiators
Potentiators were developed for CFTR mutant proteins that
are expressed at the apical membrane of epithelial cells
but are functionally impaired. HTS performed by Vertex
pharmaceuticals involving 280,000 small molecule compounds
led to the discovery of the potentiator VX-770 (Generic name:
Ivacaftor; Trade name: Kalydeco) (Van Goor et al., 2010).
Ivacaftor corrects the gating impairment of Class III mutations.
Its use has now been extended beyond the most common Class
III G551D-CFTR mutation, to additional Class III mutations, as
well as CFTR mutations with conductance (Class IV−R117H) or
biosynthesis (Class V−3,849 + 10 kb C>T) defects. In clinical
studies of participants with G551D-CFTR mutations, the impact
of Ivacaftor on CFTR was evidenced by normalization of sweat
Cl−, improved lung function (10% mean increase in FEV1),
reduced episodes of pulmonary exacerbations and improved
body mass index (BMI) (Accurso et al., 2010; Ramsey et al., 2011;
Davies et al., 2013).
Correctors
The potentiators’ mode of action does not benefit the majority
of the CF population who have the Class II F508del-CFTR
mutation, as F508del-CFTR is degraded while transitioning
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TABLE 1 | CFTR mutation class and current modulator therapeutic approach.
Mutation
class
Molecular defect Type of mutation Therapeutic approach Approved or drugs in clinical trial Mutation examples
IA∼ No mRNA synthesis Large deletions Bypass therapies (Activate
alternative Cl− channels)
– Dele2, 3(21 kb)
1717-1G->A
621+1G->T
IB∼ Protein synthesis Nonsense (PTC),
Frame-shift, Splicing
Read-through compounds Phase 2: QBW276, SPX-101
Phase 1: AZD5634, BI443651
G542X, W1282X
II Trafficking Missense Correctors and potentiators Approved: Orkambi, Symdeko
Phase 3: VX-445#, VX-659#
Phase 2: VX-152#, VX-440#,
GLPG2222, GLPG2737, FDL169
Phase 1: PTI-801
F508del, R560T, A561E
III Channel
Gating
Missense Potentiators Approved: Ivacaftor
Phase 2: VX-561, QBW251,
GLPG1837, GLPG2451, GLPG3067
Phase 1: PTI-808
G551D, S1251N, G178R
IV Conductance Missense Potentiators Approved: Ivacaftor R334W, R347P, R117H
V Protein synthesis Missense,
Alternative splicing
Correctors, Potentiators,
Antisense Oligonucleotides
Approved: Ivacaftor 3849+10kbC>T, 3272-26A>G,
2789+5G>A
VI Reduced CFTR
stability at PM
Missense,
Frameshift
Stabilizers – 120del23, N287Y, Q1412X
Compounds starting with VX are developed by Vertex Pharmaceuticals, GLPG byGalapagos NV and AbbVie, FDL, Flatley discovery lab; QBW, Novartis pharmaceuticals; PTI, Proteostasis
therapeutics; SPX, Spyryx biosciences; AZD, AstraZeneca; BI, Boehringer ingelheim; Orkambi, VX-809+VX-770; Symdeko, VX-661+VX-770; Ivacaftor, VX-770; #Triple combination
therapy with VX-661 and VX-770. PTC, Premature termination codons; PM, Plasma membrane; ∼, classification is based on (Marson et al., 2016).
through the endoplasmic reticulum, with very little or no
mutant protein reaching the apical membrane of epithelial
cell. Effective rescue of the F508del mutation thus requires
chaperones that can repair defective protein folding and rescue
trafficking of the mature CFTR to the plasma membrane.
VX-809 (Generic name: Lumacaftor; available as Lumacaftor-
Ivacaftor combination therapy—Trade name Orkambi) restored
F508del-CFTR channel activity to 15% of wild-type CFTR in
in vitro preclinical testing performed in primary airway epithelial
cells (Van Goor et al., 2012). This result led to Lumacaftor
monotherapy clinical trials in CF patients homozygous for the
F508del-CFTR mutation, where a significant improvement in
sweat Cl− concentrations were observed but lung function
remained unchanged (Clancy et al., 2017). Considering that
F508del channel gating defect, administration of Lumacaftor-
Ivacaftor combination therapy was proposed as a solution
that may augment correction of CFTR function to clinically
significant levels.
Combination Therapy
Lumacaftor-Ivacaftor combination therapy increased CFTR
activity at the plasma membrane in vitro (Van Goor et al., 2012).
However, results from phase III trials in children and adults
homozygous for the F508del-CFTR mutation showed that the
combination therapy failed to produce the magnitude of clinical
improvements observed with Ivacaftor. While a reduction in
pulmonary exacerbations and improved BMI was observed,
there was only a modest improvement in lung function (2–
3%) (Boyle et al., 2014; Wainwright et al., 2015). In addition,
CF patients receiving Lumacaftor-Ivacaftor combination therapy
reported unwanted side effects such as dyspnoea, liver damage,
and bronchospasm. Lumacaftor is also associated with significant
drug-drug interactions which alter its pharmacokinetic profile
and potentially hamper its therapeutic efficacy (Talamo Guevara
and McColley, 2017). Tezacaftor is a new CFTR corrector
with an improved pharmacokinetic profile, longer half-life and
less drug-drug interactions compared to Lumacaftor. It has
recently been approved as a combination therapy with Ivacaftor
(Trade name: Symdeko/Symveki) for the treatment of patients
homozygous for F508del mutation by the Food and Drug
Administration (FDA) and European Medicines Agency. Phase
III clinical trials data showed that improvement in lung function
with Tezacaftor-Ivacaftor combination therapy was generally
comparable or better than those observed in patients treated with
Lumacaftor-Ivacaftor combination therapy (Rowe et al., 2017;
Taylor-Cousar et al., 2017). It is notable however that while
overall benefit was demonstrated, individual patient responses
have been heterogeneous in the clinical trials of both Lumacaftor-
Ivacaftor and Tezacaftor-Ivacaftor.
Theratyping
It is now known that patients display a spectrum of responses to
CFTR-modulator drugs despite having the same CFTR mutation
variant (Wainwright et al., 2015; Donaldson et al., 2018). This
suggests that although the current classification system may be
an important indicator for prognosis and disease severity in CF,
it is inadequate for predicting how individual patients respond
to therapy. Indeed, in vitro experimental studies have shown
that contrary to findings in the Class II F508del-CFTR mutation,
other Class II processing mutations such as N1303K, R560S, and
G85E could not be rescued by Lumacaftor treatment (Awatade
et al., 2015, 2018; Dekkers et al., 2016b; Lopes-Pacheco et al.,
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2017). These results suggest that the underlying pathomechanism
of each CFTR mutation is distinct and that individualized
strategies to restore their function may be warranted.
To address this, CFTR mutations have been classified
according to their response to modulator compounds. This
approach termed “theratyping,” groups together patients who
harbor different CFTRmutations but respond to the same CFTR-
directed compounds. It is clear that treatment regimens of the
future will need to take into consideration the individual’s genetic
makeup and not just their CFTR mutations. A personalized
approach will optimize patient’s clinical outcomes by accounting
for the specific genetic mutations of the individual patient.
TOWARD PERSONALIZED MODULATOR
THERAPY
One of the major hurdles to the development of novel treatment
regimens in CF is the bench-to-bedside translation of scientific
knowledge. Many drugs that perform well in a laboratory setting
fail to advance in clinical trials, largely due to inappropriate
selection of in vivo and in vitromodels for HTS. In the context of
CF, animal models and immortalized epithelial cell lines do not
fully portray patient-specific disease phenotypes. Animal models
of CF have provided insights into disease pathophysiology.
However, their generation is time consuming, expensive, and
more importantly they poorly represent the full repertoire of
diseasemanifestations in individual patients. For instance, mouse
models of CF do not have lung disease and bacterial infections,
attributed to the compensatory effect of a secondary Cl− ion
channel (Lavelle et al., 2016). On the other hand, immortalized
epithelial cell lines derived from primary patient material have
contributed tremendously to CF research, but not without
limitations. Their generation from primary patient material is
very inefficient. It involves extensive adaptation and selection to
in vitro 2-D culture conditions, as only rare clones are able to
expand and be maintained over many passages. Furthermore,
these cell lines may have undergone substantial genetic changes
and no longer retain features of the original parental cells. Drug
development pipeline for new CFTR-directed compounds have
relied heavily on unpolarized Fischer rat thyroid (FRT) epithelial
cell lines. It is thus not surprising that this model has a higher
propensity of false-positive and false-negative “hits” compared
to that performed in primary human bronchial epithelial (HBE)
cells.
PATIENT-DERIVED ORGANOTYPIC
CELLULAR MODELS FOR PERSONALIZED
MEDICINE
Although CF is a monogenic disease, the diverse mutation
variants identified within the CFTR gene as well as the presence
of modifier genes (known and unknown), warrants adoption
of new technologies to extend research capabilities. There is a
clear unmet need for a representative library of patient-specific
epithelial cell models for disease modeling, preclinical testing of
drug response, and biobanking for future drug discovery. The
cell models can be derived from embryonic stem cells (ESCs),
induced pluripotent stem cells (iPSCs), or tissue-resident adult
stem cells. Whereas, ethical concerns pertaining the source of
human ESC, limit their use in research, generation of CFTR gene
corrected iPSC lines enable disease modeling, drug discovery and
toxicology studies [reviewed in (Pollard and Pollard, 2018)]. In
this Review, we focus on airway and intestine epithelium models
derived from adult stem cells.
Human Airway Epithelial (HAE) Cells
The pulmonary epithelium is divided into three regions;
upper (nasal and oral cavities), lower (trachea and primary
bronchi), and distal small airway epithelia (alveolar). Persistent
inflammation, bacterial colonization, and airway structural
changes in CF occur in the lower respiratory tract. Primary
HBE cells are therefore the gold standard for studying CF
disease pathogenesis and evaluating CFTR functional response
(Van Goor et al., 2006; Awatade et al., 2015). HBE cells can
be isolated from biopsy samples, lung explants and cadavers.
Explanted lung and post-mortem samples from individuals with
CF provide high cell yield. However, the extensive damage to
the tissue, particularly the epithelial cell layer, plus the presence
of chronic microbial colonization present technical challenges
to establishing successful ex vivo cultures. Acquisition of airway
biopsies or brushings involves highly invasive procedures, while
bronchoalveolar lavage (BAL) fluid and induced sputum samples
usually do not provide sufficient cell counts to initiate culture.
Therefore, supply of CF patient-derived HBE cells are often
limited and hard to come by.
Human nasal epithelial (HNE) cells are increasingly used
as surrogates for the lower airway epithelium in CF research
(de Courcey et al., 2012; Brewington et al., 2018a). HNE
cells demonstrate many characteristics common to HBE
cells including the ability to form polarized, pseudostratified
epithelium mimicking in vivo airways and the expression of ion
channels such as CFTR. Their advantage is the lack of need for
invasive procurement (Clarke et al., 2013). HNE cells are grown
using the same culture media and protocol as for HBE cells.
Human Airway Epithelial (HAE) Cell Culture Models
Primary human airway epithelial cells are conventionally
cultured as monolayers (2-D cultures). Expansion of epithelial
cells is often necessary in the initial passages for biobanking
purposes and to generate enough cell numbers needed to
differentiate cells under air-liquid interface (ALI) conditions.
HBE cells are most “in vivo” like when fully differentiated;
they display a striking phenotypic resemblance to the lower
airway epithelium. They form pseudostratified epithelium
with mucociliary differentiation indicated by the presence of
functional beating cilia and mucus secretion. They also exhibit
characteristic epithelial barrier functions, including expression
of cell junctional proteins and the development of robust trans-
epithelial electrical resistance (TEER) values (Berube et al., 2010).
The polarized, differentiated phenotype is critical for in vitro
measurement of CFTR function as the protein is primarily
expressed at the apical surface of ciliated cells. While ALI
cultures accurately represent in vivo phenotypes, their wider use
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is deterred by limited propagation of cells in culture, attributed
to squamous transformation and cellular senescence (Gentzsch
et al., 2017). To date, three expansion methods have been used to
extend the lifespan of cells and delay cellular senescence beyond
that of the standard cultures.
Improved Cell Expansion Culture Methods
Conditionally reprogrammed cells (CRCs) are generated by co-
culturing patient-derived airway epithelial cells with irradiated
fibroblast feeder cells. Specialized conditioned media (termed F-
Media) which contains Rho-associated protein kinase (ROCK)
inhibitor, promotes serial passages of airway epithelial cells
and enhances population doubling without compromising the
characteristic epithelial cell morphology. Both ROCK inhibitor
and the feeder layer are essential in maintaining the stem cell-like
phenotype evident in CRCs (Reynolds et al., 2016; Martinovich
et al., 2017). Their removal results in differentiated cell lines,
with intact barrier function and the ability to polarize and form
mucociliary epithelium. CFTR-mediated Cl− transport in these
cells is also preserved.
A modified CRCs protocol using BEGM, ROCK inhibitor
and an irradiated feeder layer cultured in reduced oxygen
concentration (2%) demonstrated some advantage over the
standard CRCs. The modified CRCs could support airway
epithelial cell growth up to passage 10 with robust formation
of pseudostratified epithelium at the extended passage, although
a modest decrease in CFTR-dependent Cl− transport was
observed. Meanwhile, reduced numbers of ciliated cells and
goblet cells were observed in standard CRCs cultures at P10 and
robust TEER could not be established (Peters-Hall et al., 2018).
A feeder-free culture protocol that relies on disruption of
SMAD signaling pathway through inhibition of dual ligands,
transforming growth factor-beta (TGF-β) and bonemorphogenic
protein (BMP), showed airway epithelial cells could be expanded
up to 18–25 passages without loss of proliferative potential (Mou
et al., 2016). Combined TGF-β/BMP inhibition led to basal cell
hyperplasia with hyper-proliferative p63 cells (basal cell marker)
and produced homogenous, tightly packed cells, resembling stem
cell morphology. Epithelial cells expanded using dual SMAD
inhibition method can undergo mucociliary differentiation up
to P12 with preserved TEER although Na+ currents and Cl−
conductance declined fairly rapidly after serial passage 6 (Mou
et al., 2016).
Three-Dimensional Airway Spheroids and
Organoids
Two-D cultures lack a third dimension, the scaffolding
extracellular matrix (ECM), which establishes intercellular cues
or network in the in vivo airway epithelium. Therefore, 3-D
cell cultures are a major area of development, where cells are
cultured in a matrix (such as matrigel) or are cultured in such
a manner that they develop ECM-like scaffolds between them,
thus mimicking the in vivo phenotype more faithfully. While
cell-derived ECMs such as Matrigel have been most commonly
used for development of organoids, their undefined components
introduce inconsistency in replicating the native 3-D culture
environment (Czerwinski and Spence, 2017). To overcome
this challenge, new biomaterial systems, such as polymers and
hydrogels are being developed [reviewed in (Dye et al., 2017)].
Different methods for generating organoids (or spheroids)
from human lung cells have been described to date, each
producing organoids with distinct definitive structure and
cellular compositions. Barkauskas and colleagues have elegantly
reviewed the different lung organoids (airway organoids
inclusive) established from varying lung progenitor cell
populations, including basal cells in the proximal airways,
secretory club Clara cells in bronchioles and alveolar type II
cells in the alveoli, as well as those from embryonic and iPSCs
(Barkauskas et al., 2017). Given CFTR is primarily expressed
at the apical surface of ciliated cells and recently discovered
in the pulmonary ionocytes in tracheal epithelium (Montoro
et al., 2018; Plasschaert et al., 2018), only airway organoids
displaying proximal differentiation are discussed here in light
of their relevance for measuring CFTR functional response
(Table 2).
Three-Dimensional Airway Explant Spheroid
(ECM—Free)
Airway spheroid cultures were first described in 1991 when
nasal epithelial multicellular spheroids were generated from
non-dissociated nasal epithelial sheets (Bridges et al., 1991).
These explant spheroids were maintained in culture media (no
matrigel) and were reported to form rapidly, within 2–5 days.
Explant spheroids have an apical-membrane-out orientation;
apical ciliated cells face the media bath and the basolateral
membrane lines the fluid-filled lumen (Bridges et al., 1991).
Pedersen and colleagues later found amiloride-sensitive Na+
transport drives changes in the lumen size, suggesting nasal
spheroids may be a useful model for ion/fluid transport
studies and for investigating diseases associated with defective
ion channels such as cystic fibrosis (Pedersen et al., 1999).
Nasal spheroids were also responsive to forskolin stimulation
(Guimbellot et al., 2017). As the CFTR-expressing apical side
of nasal spheroids face outward, forskolin causes the outflow
of fluid from the lumen to the exterior bath and the spheroids
to shrink in size. This response was blunted in spheroids
established from CF patients but could be partially rescued by
CFTR modulators (Guimbellot et al., 2017). Notably, successful
spheroids have also been established from bronchial brushings,
although CFTR function was not tested in the study (Deslee
et al., 2007). Interestingly, no evidence of cell proliferation was
observed throughout the nasal spheroid formation process and
the spheroids plateaued in size once fully formed. This suggests
that the spheroids are self-organizing aggregates of terminally
differentiated epithelial cells only (Castillon et al., 2002). While
spheroids may be ready for ex vivo CFTR measurement rapidly,
they are short-lived, lasting for up to 12 weeks only and
biobanking for future drug screening is not possible (Guimbellot
et al., 2017).
Three-Dimensional Spheroid From Airway Basal
Progenitor Cells
Airway spheroids, both bronchial and nasal can also be
derived from primary airway basal cells embedded in the
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TABLE 2 | Comparison of three-dimensional organotypic airway epithelial culture methods.
Respiratory—nasal and bronchial
Airway explant spheroid Airway basal cell spheroid Long term expanding airway
organoid
Method 1—Dome Method 2–25% layer
Cultures
Cellular source Freshly isolated non-dissociated
airway epithelial sheets
Airway basal progenitor cells expanded as
traditional primary cultures or conditionally
reprogrammed cultures
Lung biopsies and cells from
BAL fluid
Media Standard, non-differentiating
culture media e.g., BEGM
Differentiation media—same as those used for 2D
ALI cultures
Media containing biochemical
cues for self-renewal. Content:
Advanced DMEM/F12
R-Spondin 1
Noggin
FGF 7
FGF 10
A83-01
Y-27632
SB202190
B27 supplement
N-Acetylcysteine
Nicotinamide
Glutamax
Require ECM (matrigel) No Yes Yes
Constitute
differentiated epithelium
structure
Yes (ex vivo—already
differentiated)
Yes (after 14–21 days culture) Yes (duration to form not
reported)
Orientation of apical
ciliated side
Facing outwards (media) Facing inwards (lumen) Facing inwards (lumen)
Use of cultures End-point experiments End-point experiments Can be passaged for on-going
cultures (reported up to P18)
CFTR functional assay Yes—spheroids shrink when
CFTR is activated
Yes—spheroids swell when CFTR is activated Yes—spheroids swell when
CFTR is activated
Cryopreservation No No Not reported
References Bridges et al., 1991
Pedersen et al., 1999
Deslee et al., 2007
Guimbellot et al., 2017
Danahay et al., 2015
Hild and Jaffe, 2016
Brewington et al., 2018c
Sachs et al., 2018
Zhou et al., 2018
2D, Two-dimensional; ALI, Air-liquid interphase; BAL, Bronchoalveolar lavage; BEGM, Bronchial epithelial cell growth media; ECM, Extracellular matrix; FGF, Fibroblast growth factor;
TGF-β, Transforming growth factor-beta.
basement membrane matrix matrigel (Hild and Jaffe, 2016;
Brewington et al., 2018c). Matrigel is fundamental for the
formation of intact spheroids, with a lumen surrounded by
a slightly thickened wall upon maturity (7–14 days) and
a complete cell-apex-in morphology (Danahay et al., 2015;
Brewington et al., 2018c). Different culture protocols using
varying concentrations of matrigel have been reported; (1) cells
are resuspended in 100% matrigel and seeded as spherical
drops, then overlaid with ALI differentiation media; (2) cells
are resuspended in 5% matrigel with ALI differentiation media
and then layered over a denser 25–40% matrigel base layer
which the cells sink into (Hild and Jaffe, 2016; Tan et al.,
2017; Brewington et al., 2018c). Method 1 (100% matrigel)
was reported to yield the best success, as the sinking method
could result in formation of some spheroids with cell-apex-out
morphology and disorganized cellular aggregates (Brewington
et al., 2018b), likely due to incomplete embedding of cells
in the denser matrigel base layer e.g., growing on top of
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TABLE 3 | Comparison of human cell models relevant for CF therapeutic application.
Cell models Established
immortalized cell lines
Pulmonary Gut
HBE Nasal Intestinal
Bronchial ALI Bronchial
organoid
Nasal ALI Nasal
organoid
Rectal
biopsies
Rectal
organoid
Organoid
2-D
monolayer
Patient-specific No Yes Yes Yes Yes Yes Yes Yes
Tissue source - Lung explants
Bronchial brushing/biopsies
Bronchoalveolar lavage fluid
Nasal brushing/curettage Rectal biopsies
Invasiveness of sample
acquisition
- +++ + ++
Easy-to-culture - Flexible
- Easy to manipulate
- Limited expansion and differentiation potential
(decreases as a function of passage)
- Long term expanding cultures
- ALI cultures take 4 weeks to
form pseudostratified epithelium
-No standardized protocol
available for airway organoids
- Long term expanding cultures
-Established and standardized protocol for
organoid
-Monolayer in development phase
Phenocopies CF lung No (prone to artifact) Yes (gold
standard)
Yes Yes Yes No No No
Phenocopies CF intestine No No No No No Yes Yes Yes
CFTR functional readout - Ussing
- Halide assay
- Ussing - FIS - Ussing - FIS ICM - FIS/SLA Ussing
Assay dynamic range Large Moderate Moderate Small Small Large Large Large
Biochemical/physiological
readout
- CFTR western blotting - CFTR western
blotting
- ASL
-CBF
- CFTR western
blotting
- CFTR
western
blotting
- CFTR
western
blotting
- CFTR
western
blotting
Drug screening - High-throughput
- Hit-to-lead drug
development
- Mid-throughput
- Checkpoint
before drugs
enter clinical
trial/use
Exploratory Mid-
throughput
Exploratory Low-
throughput
Mid-
throughput
Exploratory
Predictive value ++ +++ Exploratory Exploratory Exploratory ++ ++ Exploratory
+ + +, High; ++, Moderate; +, Low; 2-D, 2-Dimensional; ALI, Air-liquid interphase; ASL, Airway surface liquid; CBF, Cilia beating frequency; FIS, Forskolin-induced swelling; HBE,
Human bronchial epithelial; ICM, Intestinal current measurement; SLA, Steady-state lumen area.
or at the interface of the denser matrigel base layer. For
certain downstream applications such as live imaging (e.g.,
forskolin-induced swelling—see section The Cell Model of the
Future), the sinking method confers an advantage because
spheroids are suspended in the same plane and permit HTS.
We also note that successful differentiated, pseudostratified
spheroid formation has been reported from airway basal cells
maintained in the standard BEGM media and those derived
from conditionally reprogrammed culture (Hild and Jaffe,
2016; Brewington et al., 2018c). Airway basal cell spheroids
have no self-renewal capacity and are used for end-point
applications.
Three-Dimensional Airway Organoid—Long-Term
Expanding
Long term expanding human airway organoids were first
reported by Sachs et al. (Sachs et al., 2018). These organoids
were established from lung biopsies or cells isolated from BAL
fluid and then cultured in media containing biochemical cues
for self-renewal such as R-spondin, Noggin, fibroblast growth
factor (FGF) and TGF-β inhibitors. The established organoids
comprised of a polarized, pseudostratified airway epithelium
containing basal cells, ciliated cells, mucus-producing goblet
cells, and secretory club (Clara) cells. The airway organoids are
amenable to passaging by mechanical disruption every other
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week for at least a year, with no loss in proliferation reported
up to P18. In addition, single cell suspensions dissociated from
the indefinitely expanding airway organoids yield an improved
2-D ALI culture (Zhou et al., 2018). These cultures displayed
full ALI differentiation by day 12–14 as opposed to 21–28 days
for conventional cultures grown from 2-D basal cells (Zhou
et al., 2018). Together, these findings suggest the possibility of
expanding isolated primary lung epithelial cells in 3-D, given cells
maintained under conditionally reprogrammed and dual SMAD
inhibition culture conditions do not expand beyond P10 without
reaching senescence (Mou et al., 2016; Gentzsch et al., 2017). The
indefinite expansion of airway organoids alsomeans in theory the
availability of “endless” amounts of ready-to-use airway epithelial
cells.
Human Intestinal Epithelial Cells
While work in CF research has primarily focused on primary
airway epithelial cells (the gold standard), patient-derived
intestinal epithelial cells also present an invaluable resource in
characterizing the relationship between the CFTR gene mutation
and the disease phenotype. More recently, they play an important
role in the development of HTS strategies to elucidate novel drugs
for the treatment of CF.
Intestinal Organoids
Compared to human airway tissue, colon tissue damage in CF
patients is minimal and the rectal epithelium is accessible in a
less invasive manner. The abundant expression of CFTR in the
distal colon makes rectal biopsies an attractive cellular source for
interrogating CFTR function (Hug et al., 2011). Assessment of
intestinal current measurement (ICM) as a readout for CFTR
activity has provided strong evidence for the diagnostic and
prognostic utility of rectal biopsies (De Jonge et al., 2004;
Hirtz et al., 2004; Mall et al., 2004; De Boeck et al., 2006;
Taylor et al., 2009; Derichs et al., 2010; Sousa et al., 2012;
Clancy et al., 2013; Cohen-Cymberknoh et al., 2013). ICM can
be applied to biopsies collected from CF patients which are
subsequently exposed to CFTR modulators, to assess the efficacy
of treatment in a personalized manner. One concern is the
possibility of reduced penetration of modulator drug into the
biopsy tissues under ex vivo conditions. Other limitations to
the use of rectal biopsies include the small number of biopsies
collected (4–8 biopsies) and the need for all biopsies to be tested
on collection day i.e., the biopsies cannot be preserved for further
testing.
Emergence of intestinal organoids (or mini-guts) overcome
these limitations by extending the use of rectal biopsies
in cultures. Intestinal organoids can be grown from crypts
isolated from freshly isolated rectal biopsies. Crypts are rich
in Lgr5+ stem cells which grow and differentiate into self-
organizing, multicellular structures (Sato et al., 2009; Jung
et al., 2011). These organoids contain all of the distinct
intestinal cell types present in the in vivo epithelium (Leushacke
and Barker, 2014). The growth and differentiation of Lgr5+
stem cells into eventual closed epithelial structures with an
internal lumen requires a fine balance of growth factors (R-
spondin, EGF, Noggin, Wnt-3a), inhibitors of TGF-β and
BMP signaling and the basement membrane matrix (matrigel).
Intestinal organoids can be indefinitely cultured and remain
genetically and phenotypically stable upon repeated passaging
and long term culture (Ikpa et al., 2014). Capitalizing on
the high expression of CFTR in rectal tissues and rapidly
expanding stem cells, they make an attractive model for
assessment of CFTR functional response in pharmacologic
testing. They provide the added advantage to test combination
of modulators without established safety profiles as part
of pre-clinical evaluation in CF patients with rare CFTR
genotype.
FORSKOLIN-INDUCED SWELLING ASSAY
AS A PROXY FOR CFTR FUNCTION
The primary functional assay to assess CFTR activity in
organoids, the forskolin-induced swelling (FIS) assay is
CFTR dependent. This approach does not measure the net
transepithelial ionic transport. Rather, forskolin is used to
stimulate intracellular cAMP production which then activates
CFTR at the plasma membrane. CFTR activation drives chloride
and fluid flux to the organoid lumen (apical membrane facing
inwards), causing rapid swelling of organoids with functional
CFTR or those derived from non-CF subjects. This swelling
effect is significantly reduced or absent in organoids derived
from CF subjects who exhibit differing rates of FIS with different
classes of CFTR mutations and also between individuals with
the same CFTR mutation (Dekkers et al., 2013). There is
accumulating evidence that the CFTR modulator-corrected
FIS response is predictive of patient-specific clinical response,
with close correlation observed between rescued swelling and
improvement in lung function (measured by FEV1) and sweat
chloride concentration (Dekkers et al., 2016a; Guimbellot
et al., 2017; Brewington et al., 2018c). Intestinal organoids can
be disrupted to single cells to generate 2-D-monolayers on
porous membranes for electrophysiological studies. FIS was
shown to positively correlate with forskolin-induced current in
subject-matched organoid-derived monolayers, supporting the
notion that CFTR-dependent fluid secretion in rectal organoids
reflects CFTR-dependent ion transport (Zomer-van Ommen
et al., 2018)
The FIS assay has been adapted for use in airway organoids
but is much less well-characterized compared to rectal organoids
(Guimbellot et al., 2017; Brewington et al., 2018c; McCarthy
et al., 2018). Studies performed thus far, have involved cultures
from small datasets of patients. Given the lack of standardized
culture protocol for airway organoids, forskolin induces either
swelling or shrinking of airway organoid depending on the
orientation of CFTR-expressing apical epithelium (swelling for
apical membrane facing inwards organoids and vice versa).
Similar to rectal organoids, forskolin-induced changes in cross
sectional area is dependent on the severity of CFTR genotypes,
and could be altered with CFTR modulators. However, the
changes are far smaller given the lower expression of CFTR
in the airways compare to the intestine. It is noteworthy that
only a single concentration of forskolin (10µM) has been
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interrogated in airway organoids FIS, while a total of eight
concentrations (0.008–5µM) were used in rectal organoids
(Dekkers et al., 2016a; Guimbellot et al., 2017; Brewington
et al., 2018c). To detect CFTR rescue with adequate resolution
and sensitivity, higher-powered objectives are used resulting
in lower throughput application compared to rectal (Dekkers
et al., 2016a; Guimbellot et al., 2017; Brewington et al., 2018c).
Establishment of a broader assay dynamic range may facilitate
higher throughput use of FIS in airway organoids. Although
preliminary, favorable correlation between in vitro FIS response
to clinical response FEV1, sweat chloride concentration and BMI
have been reported (Brewington et al., 2018c; McCarthy et al.,
2018).
THE CELL MODEL OF THE FUTURE
In this Review, we described the rapidly developing field of
organoid models specific to CF. Organoids, with their close
resemblance to the human organs most affected by CF disease,
hold great appeal for translational research. The capacity
to adapt these models for assays such as FIS is important
for theratyping and for conferring decisions on personalized
CFTR pharmacotherapy. This provides an almost immediate
application of in vitro research findings in the clinical setting.
Nonetheless, it is apparent that each model has respective
strengths and limitations (Table 3). The question as to which
model has the essential features for precision medicine in CF and
best predicts the long-term clinical benefits of a drug remains. Is
it sufficient to use just one model and if so which cell model is
best?
Intestinal organoids are the most developed so far amongst
the 3-D model systems and seemingly an easier model to
establish. But how representative is the intestinal epithelium
to its respiratory counterpart? There are clear physiological
differences between the airway mucosal surface and the gut. First,
alternative ion channels critical for solute and water transport
in the airways such as ENaC and calcium-activated chloride
channels (CaCC), are either absent or present in negligible
amounts in the gut to be functional (Rajendran et al., 2018). A
modified swelling assay showed airway but not rectal organoids
swell upon addition of Eact, an activator of the alternative
chloride channel TMEM16A (Sachs et al., 2018). Second, there
is no mucociliary clearance in the gastrointestinal tract. These
differences highlight the need for organoids of bronchial or
nasal epithelial origin to provide a closer resemblance to the
in vivo airways. It then seems logical that one will need to choose
the most appropriate 3-D cell culture model for each specific
application.
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